&NA;Palonosetron (RS 25259, RS 25259 197) is a novel high affinity serotonin 5-HT3receptor antagonist. There is some evidence to suggest that this compound interacts with the receptor in a different manner to gran...
详细信息
&NA;Palonosetron (RS 25259, RS 25259 197) is a novel high affinity serotonin 5-HT3receptor antagonist. There is some evidence to suggest that this compound interacts with the receptor in a different manner to granisetron. Roche Bioscience is conducting phase III clinical trials in the US with palonosetron for the treatment of postoperative- and chemotherapy-induced *** was more effective than ondansetron in preventing chemotherapy-induced emesis in preclinical studies. Preliminary clinical studies indicate that palonosetron reduces postoperative vomiting, but like other 5-HT3antagonists, seems to increase postoperative headaches. Palonosetron has had questionable efficacy in high risk patients undergoing major procedures. However, these results are but preliminary and the future of palonosetron as an antiemetic agent will be determined by the results of large, comparative clinical trials.
&NA;Lerisetron (F 0930RS, F 0930) is a serotonin 5-HT3receptor antagonist with potential as an antiemetic agent. Lerisetron is currently undergoing phase II trials with FAES in Spain. With the exception of Spain a...
详细信息
&NA;Lerisetron (F 0930RS, F 0930) is a serotonin 5-HT3receptor antagonist with potential as an antiemetic agent. Lerisetron is currently undergoing phase II trials with FAES in Spain. With the exception of Spain and Portugal, lerisetron is available for licensing worldwide.
&NA;Zatosetron (LY 277359, LY 19167) is a serotonin 5-HT3receptor antagonist undergoing phase III clinical trials with Eli Lilly in the US for treatment of chronic anxiety. Phase II trials in Japan have been disco...
详细信息
&NA;Zatosetron (LY 277359, LY 19167) is a serotonin 5-HT3receptor antagonist undergoing phase III clinical trials with Eli Lilly in the US for treatment of chronic anxiety. Phase II trials in Japan have been discontinued. Zatosetron has also shown promise as an antiemetic agent and is undergoing phase II trials in the US for this indication. AUS phase II clinical trial of zatosetron failed to demonstrate significant improvement in patients with migraine when the drug was administered as a single IV infusion.
Background Sarpogrelate, a serotonin blacker, has been reported to inhibit the serotonin-induced proliferation of rat aortic smooth muscle cells. The aim of this study was to investigate whether sarpogrelate reduces r...
详细信息
Background Sarpogrelate, a serotonin blacker, has been reported to inhibit the serotonin-induced proliferation of rat aortic smooth muscle cells. The aim of this study was to investigate whether sarpogrelate reduces restenosis after coronary stenting as a result of prevention of intimal hyperplasia. Methods We examined 79 patients with stable angina undergoing elective coronary stenting on de novo lesions of native coronary arteries in a prospective, randomized trial. All enrolled patients received aspirin and ticlopidine, and one third of the patients were assigned to receive oral sarpogrelote. Results Treatment with sarpogrelate in addition to aspirin and ticlopidine caused no major adverse cardiovascular events or hemorrhagic adverse effects during the 6-month follow-up period. The restenosis rate in the group of patients receiving sarpogrelate was 4.3%, which was significantly lower than the 28.6% rate found in the group of patients not receiving sarpogrelate. Conclusions Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may ploy an important role in stent restenosis.
The serotonergic system has been implicated in the pathophysiology of neurally mediated hypotension. The present pilot study suggests that 5-HT3 receptor antagonism with granisetron attenuates the early sympathetic co...
详细信息
The serotonergic system has been implicated in the pathophysiology of neurally mediated hypotension. The present pilot study suggests that 5-HT3 receptor antagonism with granisetron attenuates the early sympathetic component of neurally mediated syncope, and may contribute to the abolishment of syncope or presyncope upon head-up tilt testing.
暂无评论